Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841924 | 0.83 | MAPT (0.62) | GABRA5ALDH1A1MAPTKMT2ANNMT | |
| SCHEMBL14480387 | 0.83 | ACACB (0.48) | ALDH1A1MAPTKMT2ANNMTACACB | |
| SCHEMBL5013585 | 0.81 | NNMT (0.67) | ALDH1A1MAPTNNMTACACBSMN1; SMN2 | |
| SCHEMBL30464201 | 0.81 | NNMT (0.67) | ALDH1A1MAPTNNMTACACBSMN1; SMN2 | |
| SCHEMBL27875916 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2ANNMTACACB | |
| SCHEMBL9944378 | 0.79 | HDAC1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28934086 | 0.78 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4655916 | 0.78 | SMN1; SMN2 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3869968 | 0.78 | POLB (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9944384 | 0.78 | CA12 (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| CN-1280561-A | Amidocarboxylic acid derivatives | SANKYO CO (JP) | 2001-01-17 | — | — | CN | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | CA12 3105/4885CA1 3246/4885CA2 2273/4885 |
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | PPARG, PPARD, PPARA | CA12 4883/4885CA1 4882/4885CA2 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.